The above results suggest that CASP4 influences the activation, proliferation, and infiltration of immune cells via the interaction of IL-1β with various immunomodulatory factors, chemokines, and their receptors, to affect the efficacy of immunotherapy for gliomas. This evidence concerns the gene CASP4 and central nervous system cancer.